A real‑world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer

Jin,Ying; Chen,Yamei; Yu,Xinmin; Shi,Xun

doi:10.3892/ol.2018.8444

A real‑world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer

Authors:
- Ying Jin
- Yamei Chen
- Xinmin Yu
- Xun Shi
View Affiliations

Affiliations: Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: April 5, 2018 https://doi.org/10.3892/ol.2018.8444
Pages: 8703-8710

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Crizotinib is an anti‑cancer drug with a substantial beneficial effect in advanced non‑small‑cell lung cancer (NSCLC) patients harboring anaplastic lymphoma kinase (ALK) rearrangement. However, the real‑world data currently available on this drug are limited. Thus, the present study aimed to retrospectively examine the treatment patterns and survival outcome of 83 advanced NSCLC patients with ALK rearrangement in a single center in China. Of the 83 patients enrolled, 33 (39.8%) patients received crizotinib and the remaining 50 (60.2%) patients received chemotherapy as the initial therapy. The first‑line use of crizotinib prolonged the PFS1 (progression‑free survival to the first detection of subsequent disease progression) compared with chemotherapy (median, 18.5 vs. 4.9 months; P<0.001), however, it did not prolong the overall survival (OS; P=0.802). At the last follow up, 71 (85.5%) patients had received crizotinib and 12 (14.5%) patients were crizotinib‑naive. Patients who had received crizotinib exhibited a significantly longer OS as compared with those who were crizotinib‑naive [hazard ratio (HR) for mortality, 0.279; 95% confidence interval, 0.107‑0.727; P<0.05). Among the 71 patients who had received crizotinib, this was administered as a first‑line therapy in 33 (46.5%) cases, as a second‑line therapy in 22 (31.0%) cases and after the second‑line therapy in 16 (22.5%) cases. No significant difference in the OS among the three groups was observed (P=0.577). The Cox multivariate analysis identified the following independent negative prognostic factors for OS: Smoking history (HR=4.565), liver invasion at diagnosis (HR=4.294) and bone invasion at diagnosis (HR=2.587). In addition, the use of crizotinib (HR=0.319) was identified as a positive prognostic factor for OS. In conclusion, the present real‑world study revealed that the use of crizotinib improved the long‑term survival of patients with ALK‑positive advanced NSCLC. There was no difference in survival outcome between patients with initial use of crizotinib and those with subsequent use of crizotinib after first‑line therapy.

View Figures

View References

1	Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Boolell V, Alamgeer M, Watkins DN and Ganju V: The evolution of therapies in non-small cell lung cancer. Cancers. 7:1815–1846. 2015. View Article : Google Scholar : PubMed/NCBI
4	Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
5	Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cacner. Cell. 131:1190–1203. 2007. View Article : Google Scholar : PubMed/NCBI
6	Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, et al: An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67:4408–4417. 2007. View Article : Google Scholar : PubMed/NCBI
7	Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, et al: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol. 13:1011–1019. 2012. View Article : Google Scholar : PubMed/NCBI
8	Crino L, Kim D, Riely GJ, Janne PA, Blackhall FH, Camidge DR, Hirsh V, Mok T, Solomon BJ, Park K, et al: Initial phase II results with crizotinib in advanced ALK-posivie non-small cell lung cancer (NSCLC): PROFILE 1005. ASCO Meet Abstr. 29 15 Suppl:75142011.
9	Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cacner. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
10	Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
11	Lu S, Mok T, Lu Y, Zhou J, Shi Y and Sriuranpong V: Phase 3 study of first-line crizotinib vs pemetrexed-cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 34 15 Suppl:90582016.
12	Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H and Goldstraw P: International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members and Participating Institutions: The IASLC lung cancer staging project: The new database to inform the eighth edition of the TNM classfication of lung cancer. J Thorac Oncol. 9:1618–1624. 2014. View Article : Google Scholar : PubMed/NCBI
13	Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, Yatabe Y, Tubbs RR and Hirsch FR: An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol. 9:631–638. 2014. View Article : Google Scholar : PubMed/NCBI
14	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
15	Melosky B: Current treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. Front Oncol. 7:382017. View Article : Google Scholar : PubMed/NCBI
16	Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, et al: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 15:5216–5223. 2009. View Article : Google Scholar : PubMed/NCBI
17	Zhang YG, Jin ML, Li L, Zhao HY, Zeng X, Jiang L, Wei P, Diao XL, Li X, Cao Q and Tian XX: Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT-PCR on paraffin-embedded tissues. PLoS One. 8:e648212013. View Article : Google Scholar : PubMed/NCBI
18	Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Barón AE, Franklin WA, Aisner DL, et al: Oncogene status predicts patterns of metastatic spread in treatment-naïve non-small cell lung cancer. Cancer. 118:4502–4511. 2012. View Article : Google Scholar : PubMed/NCBI
19	Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, et al: CH5424802(RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1–2 study. Lancet Oncol. 14:590–598. 2013. View Article : Google Scholar : PubMed/NCBI
20	Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, Hartge P and Gapstur SM: 50-year trends in smoking-related mortality in the United States. N Engl J Med. 368:351–364. 2013. View Article : Google Scholar : PubMed/NCBI
21	Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, McAfee T and Peto R: 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 368:341–350. 2013. View Article : Google Scholar : PubMed/NCBI
22	Chen G, Chen X, Zhang Y, Yan F, Fang W, Yang Y, Hong S, Miao S, Wu M, Huang X, et al: A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer. Cancer Med. 6:953–961. 2017. View Article : Google Scholar : PubMed/NCBI
23	Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, Sakao Y, Hida T and Yatabe Y: Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol. 34:3383–3389. 2016. View Article : Google Scholar : PubMed/NCBI
24	Cha YJ, Kim HR and Shim HS: Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants. J Transl Med. 14:2962016. View Article : Google Scholar : PubMed/NCBI
25	Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, et al: Effect of crizotinib on overall survival in pateints with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 12:1004–1012. 2011. View Article : Google Scholar : PubMed/NCBI
26	Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, et al: Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol. 33:1881–1888. 2015. View Article : Google Scholar : PubMed/NCBI
27	Camidge DR: Taking aim at ALK across the blood-brain barrier. J Thorac Oncol. 8:389–390. 2013. View Article : Google Scholar : PubMed/NCBI
28	Metro G, Lunardi G, Floridi P, Pascali JP, Marcomigni L, Chiari R, Ludovini V, Crinò L and Gori S: CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol. 10:e26–27. 2015. View Article : Google Scholar : PubMed/NCBI
29	Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, et al: Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: A phase II global study. J Clin Oncol. 34:661–668. 2016. View Article : Google Scholar : PubMed/NCBI
30	Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, et al: Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial. Lancet Oncol. 17:234–242. 2016. View Article : Google Scholar : PubMed/NCBI
31	Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W and Wilner KD: CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 29:e443–445. 2011. View Article : Google Scholar : PubMed/NCBI
32	Metro G, Lunardi G, Floridi P, Pascali JP, Marcomigni L, Chiari R, Ludovini V, Crinò L and Gori S: CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol. 10:e26–27. 2015. View Article : Google Scholar : PubMed/NCBI
33	Ou SH, Jänne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, Crinò L, Selaru P, Cohen DP, Clark JW and Riely GJ: Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol. 25:415–422. 2014. View Article : Google Scholar : PubMed/NCBI
34	Hong X, Chen Q, Ding L, Liang Y, Zhou N, Fang W, Chen X and Wu H: Clinical benefit of continuing crizotinib therapy after initial disease progression in Chiniese pateints with advanced ALK-rearranged non-small-cell lung cancer. Oncotarget. 8:41631–41640. 2017. View Article : Google Scholar : PubMed/NCBI
35	Takeda M, Okamoto I and Nakagawa K: Clinical impact of continued crizotinib administration after isolated central nervous system progresssion in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol. 8:654–657. 2013. View Article : Google Scholar : PubMed/NCBI
36	Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC and Camidge DR: Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cacner. J Thorac Oncol. 7:1807–1814. 2012. View Article : Google Scholar : PubMed/NCBI
37	Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR and Guérin A: Monitoring for and characterizing crizotinib progression: A chart review of ALK-positive non-small cell lung cancer pateints. Adv Ther. 34:1673–1685. 2017. View Article : Google Scholar : PubMed/NCBI
38	Wu JJ, Savooji J and Liu DL: Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol. 9:192016. View Article : Google Scholar : PubMed/NCBI
39	Su S and Wu YL: Clinical trials of tyrosine kinase inhibitors for lung cancer in China: A review. J Hematol Oncol. 10:1472017. View Article : Google Scholar : PubMed/NCBI